MML Investors Services’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

MML Investors Services’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,000	Closed	-$18K	–	2362
2023 Q1	$18K	Hold	10,000	–	–	﹤0.01%	2013
2022 Q4	$11K	Hold	10,000	–	–	﹤0.01%	2144
2022 Q3	$23K	Hold	10,000	–	–	﹤0.01%	2061
2022 Q2	$30K	Hold	10,000	–	–	﹤0.01%	2016
2022 Q1	$68K	Hold	10,000	–	–	﹤0.01%	2031
2021 Q4	$84K	Hold	10,000	–	–	﹤0.01%	1983
2021 Q3	$74K	Hold	10,000	–	–	﹤0.01%	1928
2021 Q2	$68K	Buy	+10,000	New	+$83.1K	﹤0.01%	1879

Other funds holding JNCE

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

MML Investors Services's JNCE Position: Q2 2023 in Review

MML Investors Services sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 10,000 shares — an estimated $18K sold.

MML Investors Services first reported a position in JNCE in Q2 2021 and held it in 8 quarters. The position peaked at $84K in Q4 2021. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

MML Investors Services reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
MML Investors Services sold 10,000 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $18K.
MML Investors Services first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
MML Investors Services's Jounce Therapeutics, Inc. Common Stock position peaked at $84K in Q4 2021.
1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on MML Investors Services's 13F filing for Q2 2023, filed 14 Aug 2023.